Breadcrumb

Jung-Min Lee, M.D.

Jung-Min Lee, M.D.

  • Center for Cancer Research
  • National Cancer Institute
Women's Malignancies Branch

RESEARCH SUMMARY

Dr. Lee’s research is focused on the early clinical drug development and translational studies of targeted agents in BRCA mutation-associated breast or ovarian cancer, high-grade epithelial ovarian cancer, and triple negative breast cancer, as these diseases share the similar molecular abnormalities. Her clinical and translational research interests include examining the hypothesis of clinical synergy of the combination of targeting key proteins in the DNA damage repair pathways, cell cycle, tumor microenvironment, and immune check points in clinical trials, incorporating collected patient tissue and blood samples. She is the principal investigator of ongoing phase 1 and 2 studies, with a PARP inhibitor (olaparib) in combination with carboplatin or cediranib, and other biologic agents.

Areas of Expertise

1) ovarian cancer, 2) BRCA mutation, 3) triple negative breast cancer, 4) early clinical trials, 5) biomarkers

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them. 

Publications

Selected Key Publications

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study

Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee MJ, Bagheri MH, Botesteanu DA, Steinberg SM, Minasian L, Ekwede I, and Kohn EC.
Lancet Oncol. 19(2): 207-215, 2018. [ Journal Article ]

Targeting the PI3K/mTOR pathway augments CHK1 inhibitor-induced replication stress and antitumor activity in high-grade serous ovarian cancer

Huang TT, Brill E, Nair JR, Zhang X, Wilson KM, Chen L, Thomas CJ, Lee JM
Cancer Research. 80(23): 5380-5392, 2020. [ Journal Article ]

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

Pettitt SJ, Krastev DB Brandsma I, Dréan A, Song F, Aleksandrov R, Harrell MI, Menon M, Brough R, Campbell J, Frankum J, Ranes M, Pemberton HN, Rafiq R, Fenwick K, Swain A, Guettler S, Lee J-M, Swisher EM, Stoynov S, Yusa K, Ashworth A, and Lord CJ.
Nature Communications. 9: 1849, 2018. [ Journal Article ]

Safety and Clinical Activity of the PD-L1 Inhibitor Durvalumab in Combination With a PARP Inhibitor, Olaparib, or a VEGFR1-3 Inhibitor, Cediranib, in Women's Cancers: A Dose-Escalation, Phase I Study

Lee J, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, Cao L, Harrell M, Swisher E, Houston N, Botesteanu DA, Taube JM, Thompson E, Ogurtsova A, Xu H, Nguyen J, Ho TW, Figg WD, and Kohn EC.
J Clin Oncol. 35(19): 2193-2202, 2017. [ Journal Article ]

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-or-Concept Phase II Study

Lampert EJ, Zimmer A, Padget M, Cimino-Mathews A, Nair JR, Liu Y, Swisher EM, Hodge JW, Nixon AB, Nichols E, Bagheri MH, Levy E, Radke MR, Lipkowitz S, Annunziata CM, Taube JM, Steinberg SM, Lee JM
Clinical Cancer Research. 26(16): 4268-4279, 2020. [ Journal Article ]

Job Vacancies

There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.

Team

MRSP Fellow
Nitasha Gupta
Research Nurse
Nicole D. Houston, R.N., B.S.N., CCRP
Research Fellow
Tzu-Ting Huang, Ph.D.
Research Nurse
Ann McCoy, R.N.
Biologist
Jay Nair, Ph.D.
Nurse Practitioner
Britanny Brooke Solarz , R.N., B.S.N.
Research Nurse (Contr.)
Erin Villanueva, R.N.
Postbaccalaureate Fellow (CRTA)
Anu Sunkara
MSRP Student
Grant Zurcher, B.A.